Status: Recruiting
SIRT With Tremelimumab and Durvalumab for Resectable HCC
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: * Durvalumab (a type of immunotherapy) * Tremelimumab (a type of immunotherapy) * Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bead)
Participants needed: 20
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Jiping Wang, MD, PhDUpdated: Sep 2, 2025Locations: 3
Eligibility criteria
Histologically confirmed HCC (documentation of original biopsy for diagnosis is... [+18]
Participants who have received any prior treatment for HCC. [+27]